reblozyl
bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - andre præparater antianemic - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.
triolif honey & lemon 2+0,60+1,20 mg sugetabletter
karo pharma as - amylmetacresol, dichlorbenzylalkohol, lidocainhydrochlorid - sugetabletter - 2+0,60+1,20 mg
triolif mint 2+0,60+1,20 mg sugetabletter
karo pharma as - amylmetacresol, dichlorbenzylalkohol, lidocainhydrochlorid - sugetabletter - 2+0,60+1,20 mg
triolif orange 2+0,60+1,20 mg sugetabletter
karo pharma as - amylmetacresol, dichlorbenzylalkohol, lidocainhydrochlorid - sugetabletter - 2+0,60+1,20 mg
adport 1 mg kapsler, hårde
sandoz a/s - tacrolimusmonohydrat - kapsler, hårde - 1 mg
botox 200 enheder pulver til injektionsvæske, opløsning
abbvie a/s - clostridium botulinum, type a toxin - pulver til injektionsvæske, opløsning - 200 enheder
lovastatin "stada" 20 mg tabletter
stada arzneimittel ag - lovastatin - tabletter - 20 mg
lovastatin "stada" 40 mg tabletter
stada arzneimittel ag - lovastatin - tabletter - 40 mg